An observational study in Obesity, sponsored by Pennington Biomedical Research Center. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by Pennington Biomedical Research Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Obesity by Pennington Biomedical Research Center — 9 open to participants now, 13 under way, none of them phase 3. Obesity · Pennington Biomedical Research Center.
Among the 67 studies in Obesity by Pennington Biomedical Research Center, this one is the 16th largest by planned enrollment of the 22 observational ones that give a count, is one of 5 that started in 2026, is one of 22 observational ones, reaches primary completion later than 7 of the 12 other live ones, and was the 62nd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →9 of the 67 studies in Obesity by Pennington Biomedical Research Center are open now, in 1 country. Recruiting first, the newest first:
Pennington Biomedical Research Center · Sites in United States
Ages 18–50
Pennington Biomedical Research Center · Sites in United States
Healthy volunteers
Pennington Biomedical Research Center · Sites in United States
Ages 18–40 · Healthy volunteers
Pennington Biomedical Research Center · Sites in United States
Ages 22–65 · Healthy volunteers
Pennington Biomedical Research Center · Sites in United States
Ages 18–42 · Healthy volunteers
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 4 3
First in 1999; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 42 across the 45 interventional studies, 47 across the 22 observational. Of the 49 that completed or were terminated, 13 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pennington Biomedical Research Center is the lead sponsor of 284 studies on the registry; 30 are open to participants now.
5 of the studies in Obesity by Pennington Biomedical Research Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05958368Pennington Biomedical Research CenterAssessing the Value of Avocados on Glycemic Control in Type 2 Diabetes | 2026-11-30 |
| NCT04583514Pennington Biomedical Research CenterTesting the Adipose Expandability Hypothesis In Vivo During Overfeeding | 2026-12-31 |
| NCT07154719Pennington Biomedical Research CenterGLP-1R Actions on Muscle and the Skeleton | 2027-02-01 |
| NCT07530718Pennington Biomedical Research CenterBody Composition Outcomes in MS Patients | 2027-02-01 |
| NCT07095972Pennington Biomedical Research CenterContinuous Glucose Monitoring in Metabolic Surgery | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 67 studies in Obesity by Pennington Biomedical Research Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Objectives The objective of this project is to generate pilot data substantiating our hypothesis that advanced body composition measurement tools will provide more accurate and clinically relevant data on the outcomes of metabolic surgery (MS) in patients with severe obesity compared to traditional methods.
To achieve this objective, the investigators propose the following aims:
Aim 1: Evaluate the effectiveness of different body composition measurement tools in assessing outcomes in patients with severe obesity undergoing MS.
Aim 2: Assess the changes in body composition and muscle strength following MS.
Aim 3: Compare body compositions changes between SG and RYGB patients.
Background Metabolic surgery (MS) is the most effective long term obesity treatment in patients with severe obesity. The prevalence of obesity among US adults is 40.3% and the prevalence of severe obesity is 9.4% (2021-2023). Despite the prevalence and severity of obesity, there is a significant knowledge gap regarding the most effective tools for assessing body composition in this population. Traditional methods such as BMI and waist circumference may not accurately reflect changes in body composition, particularly in patients with higher BMI. Current literature on body composition measurements in patients with severe obesity undergoing bariatric surgery is limited.
Our study design and rationale are inspired by a 2003 study by Das et al., which assessed body composition using four measurement tools: the 3-compartment (3C) model, isotope dilution, densitometry, and BIA. This study involved 20 women with BMIs ranging from 37 to 76 who underwent RYGB. The findings indicated that a simple 3-compartment model using air displacement plethysmography and BIA is effective for clinical evaluation in this population. To date, this remains the only study focusing on higher BMI patients undergoing MS. However, its limitations include being conducted solely on a female population and using these four measurement tools exclusively in RYGB patients with severe obesity.
As mentioned earlier, the goal of this project is to generate pilot data substantiating our hypothesis that advanced body composition measurement tools will provide more accurate and clinically relevant data on the outcomes of MS in patients with severe obesity compared to traditional methods.
Objectives The objective of this project is to generate pilot data substantiating our hypothesis that advanced body composition measurement tools will provide more accurate and clinically relevant data on the outcomes of metabolic surgery (MS) in patients with severe obesity compared to traditional methods.
To achieve this objective, the investigators propose the following aims:
Aim 1: Evaluate the effectiveness of different body composition measurement tools in assessing outcomes in patients with severe obesity undergoing MS. The investigators hypothesize that advanced body composition measurement tools will provide more accurate and clinically relevant data on the outcomes of MS in patients with severe obesity compared to traditional methods.
Aim 2: Assess the changes in body composition and muscle strength following MS. The investigators hypothesize that 6 months post MS, patients will experience a change in muscle strength, along with a more significant decrease in fat mass compared to muscle mass.
Aim 3: Compare body compositions changes between SG and RYGB patients. The investigators hypothesize that RYGB patients will experience greater changes in subcutaneous, visceral, and total fat compared to SG patients after 6 months.
Bariatric surgery patients with BMI 40 or more
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Roux-en-Y gastric bypass surgery
Sleeve Gastrectomy
Evaluate the effectiveness of Bioimpedance Analysis (BIA) in assessing outcomes in patients with severe obesity undergoing metabolic surgery (MS).
Measurement of weight in kilograms
Time frame: Baseline and 6 months
Evaluate the effectiveness of Leg Strength and Endurance Testing in assessing outcomes in patients with severe obesity undergoing MS.
Leg muscle strength measured in in Newton-meters (Nm)
Time frame: Baseline and 6 months
Evaluate the effectiveness of BIA in assessing outcomes in patients with severe obesity undergoing MS
height in meters
Time frame: Baseline and 6 months
Evaluate the effectiveness of BIA in assessing outcomes in patients with severe obesity undergoing MS
weight and height will be combined to report BMI in kg/m\^2
Time frame: Baseline and 6 months
Evaluate the effectiveness Body MRI in assessing outcomes of body composition in assessing outcomes in patients with severe obesity undergoing MS
Measure skeletal muscle mass volume in cm\^3
Time frame: Baseline and 6 months
Evaluate the effectiveness of BIA in assessing outcomes in patients with severe obesity undergoing MS
body fat percentage in %
Time frame: Baseline and 6 months
Evaluate the effectiveness of anthropometric measurement tool in assessing outcomes in patients with severe obesity undergoing MS
Measure waist circumference in cm
Time frame: Baseline and 6 months
Evaluate the effectiveness of anthropometric measurement tool in assessing outcomes in patients with severe obesity undergoing MS
Mid-thigh circumference in cm
Time frame: Baseline and 6 months
Evaluate the effectiveness of BIA measurement tool in assessing outcomes in patients with severe obesity undergoing MS
weight and height will be combined to report BMI in kg/m\^2
Time frame: Baseline and 6 months
Evaluate the effectiveness of anthropometric measurement tools in assessing outcomes in patients with severe obesity undergoing MS
Hip circumference in cm
Time frame: Baseline and 6 months
Evaluate the effectiveness Body MRI in assessing outcomes of body composition in assessing outcomes in patients with severe obesity undergoing MS
Measure visceral adipose tissue volume in cm\^3
Time frame: Baseline and 6 months
Evaluate the effectiveness Body MRI in assessing outcomes of body composition in assessing outcomes in patients with severe obesity undergoing MS
Measure subcutaneous adipose tissue volume in cm\^3
Time frame: Baseline and 6 months
Evaluate the effectiveness of Six-Minute Walk testing in assessing outcomes in patients with severe obesity undergoing MS.
Physical endurance will be measured by the distance walked during a 6-minute walk test in meter
Time frame: Baseline and 6 months
Evaluate the effectiveness of 3D Optical Imaging in assessing outcomes in patients with severe obesity undergoing MS.
Measure body volume in cm\^3
Time frame: Baseline and 6 months
Evaluate the effectiveness of BodPod (Air Displacement Plethysmography) in assessing outcomes in patients with severe obesity undergoing MS
Measure body volume in liters
Time frame: Baseline and 6 months
Evaluate the effectiveness of BodPod in assessing outcomes in patients with severe obesity undergoing MS.
Measure body density in kilograms per cubic meter (kg/m\^3)
Time frame: Baseline and 6 months
Evaluate the effectiveness of Dual Energy X ray Absorptiometry (DXA) in assessing outcomes in patients with severe obesity undergoing MS
Measure total fat mass in kg
Time frame: Baseline and 6 months
Evaluate the effectiveness of DXA in assessing outcomes in patients with severe obesity undergoing MS
Measure lean mass /fat free mass in kg
Time frame: Baseline and 6 months
Evaluate the effectiveness of Deuterium & Bromide Dilution in assessing outcomes in patients with severe obesity undergoing metabolic surgery (MS).
Measure total body water in liter
Time frame: Baseline and 6 months
Evaluate the effectiveness of Deuterium & Bromide Dilution in assessing outcomes in patients with severe obesity undergoing MS.
Measure extracellular water in liters
Time frame: Baseline and 6 months
Plan to share: No
Started Apr 2026 (actual). Primary completion is estimated for Feb 2027, 9 months after the start.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 9 months is below that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pennington Biomedical Research Center →